Inventiva SA is a France-based company engaged in the biotechnology sector. The Company focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
企業コードIVA
会社名Inventiva SA
上場日Feb 15, 2017
最高経営責任者「CEO」Mr. Frederic Cren
従業員数- -
証券種類Ordinary Share
決算期末- -
本社所在地50 rue de Dijon
都市DAIX
証券取引所Euronext Paris
国France
郵便番号21121
電話番号33380447500
ウェブサイトhttps://inventivapharma.com/
企業コードIVA
上場日Feb 15, 2017
最高経営責任者「CEO」Mr. Frederic Cren
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし